Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
1 report, 1 independent
Updated Sep 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Gilead Sciences
American company
Related events
- Morgan Stanley issued an overweight rating on an unspecified company or stock.
- Morgan Stanley and Royal Bank of Canada initiated coverage of Csquare stock on August 10, 2026, setting ratings of overweight and outperform, respectively.
- Morgan Stanley reaffirmed an underweight rating and Citigroup restated a sell rating on Handelsbanken, reported by MarketBeat.
- Morgan Stanley, Jefferies, and Citigroup commented on Cullen/Frost Bankers, boosting targets and issuing sell/underweight ratings on July 25, 2026.
- Financial firms, including Jefferies, Morgan Stanley, and Cantor Fitzgerald, issued rating updates and lowered earnings estimates for Arcutis Biotherapeutics.